Visium Asset Management’s Neurogene NGNE Stock Holding History

Visium Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-65,081	Closed	-$11.5M	–	441
2016 Q1	$11.5M	Sell	65,081 -4,919	-7%	-$956K	0.2%	132
2015 Q4	$17.5M	Hold	70,000	–	–	0.26%	84
2015 Q3	$19.7M	Buy	70,000 +58,265	+497%	+$13.4M	0.27%	77
2015 Q2	$1.63M	Sell	11,735 -6,980	-37%	-$1.06M	0.02%	457
2015 Q1	$3.21M	Buy	18,715 +1,250	+7%	+$254K	0.05%	342
2014 Q4	$2.62M	Buy	17,465 +2,525	+17%	+$360K	0.04%	375
2014 Q3	$1.99M	Hold	14,940	–	–	0.03%	469
2014 Q2	$2.8M	Hold	14,940	–	–	0.04%	334
2014 Q1	$3.8M	Buy	+14,940	New	+$3.84M	0.06%	278

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Visium Asset Management's NGNE Position: Q2 2016 in Review

Visium Asset Management sold out of Neurogene (NGNE) in Q2 2016, closing a stake of 65,081 shares — an estimated $11.5M sold.

Visium Asset Management first reported a position in NGNE in Q1 2014 and held it in 9 quarters. The position peaked at $19.7M in Q3 2015. 34 funds tracked by Wall St. Rank hold NGNE as of Q2 2016.

Visium Asset Management reported no remaining Neurogene position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 65,081 Neurogene shares in Q2 2016, an estimated $11.5M.
Visium Asset Management first reported a position in Neurogene in Q1 2014 and held it in 9 quarters.
Visium Asset Management's Neurogene position peaked at $19.7M in Q3 2015.
34 funds tracked by Wall St. Rank held Neurogene as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.